Transfusion-transmissible infection monitoring system: A tool to monitor changes in blood safety

Transfusion

Volumn 56, Issue 6, 2016, Pages 1499-1502

  Custer, Brian ^a   Stramer, Susan L ^b   Glynn, Simone ^c   Williams, Alan E ^d   Anderson, Steven A ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMERICAN RED CROSS   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Office of Blood Research and Review   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD SAFETY; COMMUNICABLE DISEASE; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; REVIEW; TRANSFUSION; BLOOD BANK; BLOOD TRANSFUSION; THROMBOCYTE TRANSFUSION;

BLOOD BANKS; BLOOD SAFETY; BLOOD TRANSFUSION; HUMANS; PLATELET TRANSFUSION;

EID: 84974603322     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13632     Document Type: Review

References (14)

1. Ammann AJ, Cowan MJ, Wara DW, et al., Acquired immunodeficiency in an infant: possible transmission by means of blood products. Lancet 1983; 1: 956-8.
2. Epstein JS, Jaffe HW, Alter HJ, et al., Blood system changes since recognition of transfusion-associated AIDS. Transfusion 2013; 53: 2365-74.
3. Stramer SL, Dodd RY., Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013; 53: 2375-83.
4. Busch MP, Young MJ, Samson SM, et al., Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion 1991; 31: 4-11.
5. Centers for Disease Control (CDC). Update: revised Public Health Service definition of persons who should refrain from donating blood and plasma-United States. MMWR Morb Mortal Wkly Rep 1985; 34: 547-8.
6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). Revised recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products-guidance for industry. Silver Spring (MD): U. S. Food and Drug Administration; 2015.
7. Germain M., The risk of allowing blood donation from men having sex with men after a temporary deferral: predictions versus reality. Transfusion 2016; 56: 000-00.
8. O'Brien SF, Osmond L, Fan W, et al., Impact of a 5-year deferral from blood donation for men who have sex with men. Transfusion 2016; 56: 000-00.
9. Custer B, Kessler D, Vahidnia F, et al., Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. Transfusion 2014; 55: 10.
10. Transfusion-Transmissible Infections (TTI) Monitoring system (TTIMS) statement of work for DDCC and LRCC. Silver Spring (MD): U.S. Food and Drug Administration; 2015.
11. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). Final Rule: Requirements for blood and blood components intended for transfusion or for further manufacturing use. Silver Spring (MD): U.S. Food and Drug Administration; 2015.
12. Duong YT, Qiu M, De AK, et al., Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 2012; 7: e33328.
13. Kassanjee R, Pilcher CD, Keating SM, et al., Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS 2014; 28: 2439-49.
14. Delwart E, Slikas E, Stramer SL, et al., Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis 2012; 205: 875-85.